Alexion Pharmaceuticals, Inc. Company Profile

Aggregated data from the web about Alexion Pharmaceuticals, Inc.

Company Name	Alexion Pharmaceuticals, Inc.
Website	https://alexion.com
Snippet	Alexion. The FDA approved our long-acting C5 complement inhibitor for adults with generalized myasthenia gravis. Read more about our latest approval. Our Inspiration. Our Medicines. Our Research. Our Commitment. Our Company.
Type	Subsidiary
Parent	AstraZeneca
Founded	1992
Founder	Leonard Bell
Revenue	US$6.069 billion (2020)
Website	www.alexion.com
Industry	Pharmaceutical industry
Products	Eculizumab (Soliris)Ravulizumab (Ultomiris)Asfotase alfa (Strensiq)Sebelipase alfa (Kanuma)Andexanet alfa (Andexxa)
Traded as	Nasdaq: ALXN
Key people	Leonard Bell (Chairman)Ludwig N. Hantson (CEO)
Net income	US$603 million (2020)
Headquarters	Boston, Massachusetts
Total assets	US$18.103 billion (2020)
Total equity	US$11.651 billion (2020)
Number of employees	2,525 (2020)

Alexion Pharmaceuticals, Inc. is part of the United States company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.